GRP 78 directed immunotherapy in relapsed or refractory

  • Slides: 8
Download presentation
GRP 78 -directed immunotherapy in relapsed or refractory multiple myeloma - results from a

GRP 78 -directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM 6 by Leo Rasche, Johannes Duell, Inês C. Castro, Valentina Dubljevic, Manik Chatterjee, Stefan Knop, Frank Hensel, Andreas Rosenwald, Hermann Einsele, Max S. Topp, and Stephanie Brändlein haematol Volume 100(3): 377 -384 March 4, 2015 © 2015 by Ferrata Storti Foundation

Study design. Leo Rasche et al. Haematologica 2015; 100: 377 -384 © 2015 by

Study design. Leo Rasche et al. Haematologica 2015; 100: 377 -384 © 2015 by Ferrata Storti Foundation

Patients’ demographics and baseline disease characteristics. Leo Rasche et al. Haematologica 2015; 100: 377

Patients’ demographics and baseline disease characteristics. Leo Rasche et al. Haematologica 2015; 100: 377 -384 © 2015 by Ferrata Storti Foundation

Treatment emergent adverse events (TEAE). Leo Rasche et al. Haematologica 2015; 100: 377 -384

Treatment emergent adverse events (TEAE). Leo Rasche et al. Haematologica 2015; 100: 377 -384 © 2015 by Ferrata Storti Foundation

Summary of pharmacokinetic parameters. Leo Rasche et al. Haematologica 2015; 100: 377 -384 ©

Summary of pharmacokinetic parameters. Leo Rasche et al. Haematologica 2015; 100: 377 -384 © 2015 by Ferrata Storti Foundation

Pharmakokinetics: mean serum concentration profiles of PAT-SM 6 for dose days 1 and 10

Pharmakokinetics: mean serum concentration profiles of PAT-SM 6 for dose days 1 and 10 by dose level (linear). Leo Rasche et al. Haematologica 2015; 100: 377 -384 © 2015 by Ferrata Storti Foundation

Changes in M-protein from baseline to end of the trial. Leo Rasche et al.

Changes in M-protein from baseline to end of the trial. Leo Rasche et al. Haematologica 2015; 100: 377 -384 © 2015 by Ferrata Storti Foundation

PAT-SM 6 target binding (A) Immunohistochemical staining with PAT-SM 6 on paraffin-fixed sections of

PAT-SM 6 target binding (A) Immunohistochemical staining with PAT-SM 6 on paraffin-fixed sections of MM patients and flow cytometry analysis on MM cells from bone marrow. Leo Rasche et al. Haematologica 2015; 100: 377 -384 © 2015 by Ferrata Storti Foundation

Relapsed Refractory MM Patients ASH 2015 Summary ELOQUENT2Relapsed Refractory MM Patients ASH 2015 Summary ELOQUENT2
PD1 Blockade with Nivolumab in Relapsed or RefractoryPD1 Blockade with Nivolumab in Relapsed or Refractory
Nivolumab in Patients Pts with Relapsed or RefractoryNivolumab in Patients Pts with Relapsed or Refractory
How I treat relapsed and refractory Hodgkin lymphomaHow I treat relapsed and refractory Hodgkin lymphoma
Brentuximab Vedotin in Patients with Relapsed or RefractoryBrentuximab Vedotin in Patients with Relapsed or Refractory
Directed Path Directed Path Agenda Directed Path AboutDirected Path Directed Path Agenda Directed Path About
Good Regulatory Practices GRP International GRP and theGood Regulatory Practices GRP International GRP and the